BACKGROUND: Children who are treated for myeloid leukemia associated with Down syndrome (DS) experience superior survival compared with children who have myeloid leukemia without DS. To maintain excellent outcomes while avoiding toxicity, the Children's Oncology Group (COG) conducted the phase 3 trial COG A2971, the first trial solely designed to provide uniform treatment of myeloid leukemia in North American children with DS. A2971 eliminated 2 induction drugs and 3 months of maintenance therapy from the standard-timing regimen of dexamethasone, cytarabine, 6-thioguanine, etoposide, and rubidomycin/daunomycin (DCTER) used in the previous study (Children's Cancer Group [CCG] 2891). METHODS: COG A2971 was a multi-institutional, nonrandomized, clinical trial that enrolled 132 patients who had DS with either acute myeloid leukemia (n = 91) or myelodysplastic syndrome (n = 41). RESULTS: The median follow-up was 4.8 years (range, 0.8-8.6 years), the median age at diagnosis was 1.7 years (range, 0.3-13.6 years), and the median white blood cell count was 6200/μL (range, 900-164,900/μL). The remission rate (92.7% ± 6%) was similar to that reported in the CCG 2891 study (91.3% ± 5%; P = .679). The 5-year event free survival (EFS) rate was 79% ± 7% (vs 77% ± 7% in CCG 2891; P = .589), the disease-free survival (DFS) rate was 89% ± 6% (vs 85% ± 6% in CCG 2891; P = .337), and the overall survival rate was 84% ± 6% (vs 79% ± 7% in CCG 2891; P = .302). Induction day-14 bone marrow response trended toward a more favorable outcome (EFS: P = .12). Age >4 years was an adverse risk factor (5-year EFS rate: 33% ± 38% for children aged >4 years [median, 8.5 years; n = 6] vs 81% ± 7% for children ages 0-4 years [median, 1.7 years; n = 126]; P = .001). CONCLUSIONS: The COG A2971 trial reduced the chemotherapy dose and maintained survival to that achieved by the CCG 2891 trial in children who had myeloid leukemia associated with DS.
BACKGROUND:Children who are treated for myeloid leukemia associated with Down syndrome (DS) experience superior survival compared with children who have myeloid leukemia without DS. To maintain excellent outcomes while avoiding toxicity, the Children's Oncology Group (COG) conducted the phase 3 trial COG A2971, the first trial solely designed to provide uniform treatment of myeloid leukemia in North American children with DS. A2971 eliminated 2 induction drugs and 3 months of maintenance therapy from the standard-timing regimen of dexamethasone, cytarabine, 6-thioguanine, etoposide, and rubidomycin/daunomycin (DCTER) used in the previous study (Children's Cancer Group [CCG] 2891). METHODS:COG A2971 was a multi-institutional, nonrandomized, clinical trial that enrolled 132 patients who had DS with either acute myeloid leukemia (n = 91) or myelodysplastic syndrome (n = 41). RESULTS: The median follow-up was 4.8 years (range, 0.8-8.6 years), the median age at diagnosis was 1.7 years (range, 0.3-13.6 years), and the median white blood cell count was 6200/μL (range, 900-164,900/μL). The remission rate (92.7% ± 6%) was similar to that reported in the CCG 2891 study (91.3% ± 5%; P = .679). The 5-year event free survival (EFS) rate was 79% ± 7% (vs 77% ± 7% in CCG 2891; P = .589), the disease-free survival (DFS) rate was 89% ± 6% (vs 85% ± 6% in CCG 2891; P = .337), and the overall survival rate was 84% ± 6% (vs 79% ± 7% in CCG 2891; P = .302). Induction day-14 bone marrow response trended toward a more favorable outcome (EFS: P = .12). Age >4 years was an adverse risk factor (5-year EFS rate: 33% ± 38% for children aged >4 years [median, 8.5 years; n = 6] vs 81% ± 7% for children ages 0-4 years [median, 1.7 years; n = 126]; P = .001). CONCLUSIONS: The COG A2971 trial reduced the chemotherapy dose and maintained survival to that achieved by the CCG 2891 trial in children who had myeloid leukemia associated with DS.
Authors: W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange Journal: Blood Date: 1996-06-15 Impact factor: 22.113
Authors: U Creutzig; J Ritter; J Vormoor; W D Ludwig; C Niemeyer; I Reinisch; B Stollmann-Gibbels; M Zimmermann; J Harbott Journal: Leukemia Date: 1996-11 Impact factor: 11.528
Authors: Yubin Ge; Mark L Stout; Dana A Tatman; Tanya L Jensen; Steven Buck; Ronald L Thomas; Yaddanapudi Ravindranath; Larry H Matherly; Jeffrey W Taub Journal: J Natl Cancer Inst Date: 2005-02-02 Impact factor: 13.506
Authors: B J Lange; N Kobrinsky; D R Barnard; D C Arthur; J D Buckley; W B Howells; S Gold; J Sanders; S Neudorf; F O Smith; W G Woods Journal: Blood Date: 1998-01-15 Impact factor: 22.113
Authors: Alan S Gamis; William G Woods; Todd A Alonzo; Allen Buxton; Beverly Lange; Dorothy R Barnard; Stuart Gold; Franklin O Smith Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: Jeffrey W Taub; Jason N Berman; Johann K Hitzler; April D Sorrell; Norman J Lacayo; Kelley Mast; David Head; Susana Raimondi; Betsy Hirsch; Yubin Ge; Robert B Gerbing; Yi-Cheng Wang; Todd A Alonzo; Dario Campana; Elaine Coustan-Smith; Prasad Mathew; Alan S Gamis Journal: Blood Date: 2017-04-07 Impact factor: 22.113
Authors: C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Sébastien Malinge; Tim Chlon; Louis C Doré; Rhett P Ketterling; Martin S Tallman; Elisabeth Paietta; Alan S Gamis; Jeffrey W Taub; Stella T Chou; Mitchell J Weiss; John D Crispino; Maria E Figueroa Journal: Blood Date: 2013-08-26 Impact factor: 22.113
Authors: Marjolein Blink; Martin Zimmermann; Christine von Neuhoff; Dirk Reinhardt; Valerie de Haas; Henrik Hasle; Maureen M O'Brien; Batia Stark; Julie Tandonnet; Andrea Pession; Katerina Tousovska; Daniel K L Cheuk; Kazuko Kudo; Takashi Taga; Jeffrey E Rubnitz; Iren Haltrich; Walentyna Balwierz; Rob Pieters; Erik Forestier; Bertil Johansson; Marry M van den Heuvel-Eibrink; C Michel Zwaan Journal: Haematologica Date: 2013-08-09 Impact factor: 9.941
Authors: Johann K Hitzler; Wensheng He; John Doyle; Mitchell Cairo; Bruce M Camitta; Ka Wah Chan; Miguel A Diaz Perez; Christopher Fraser; Thomas G Gross; John T Horan; Alana A Kennedy-Nasser; Carrie Kitko; Joanne Kurtzberg; Leslie Lehmann; Tracey O'Brien; Michael A Pulsipher; Franklin O Smith; Mei-Jie Zhang; Mary Eapen; Paul A Carpenter Journal: Biol Blood Marrow Transplant Date: 2013-03-01 Impact factor: 5.742